- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02813746
Maternal Transcriptomic Regulation of the Preimplantation Embryo
The aim of this study is to understand the epigenetic and transcriptomic mechanisms that regulate the fetal origin of adult diseases (FOAD), either for the presence of metabolic disorders in the future mothers, such as obesity or for the exposure to certain contaminants such as tobacco.
To do that, the miRNAs profiles secreted to the endometrial fluid in obese women vs normoweight women during the window of implantation will be identified. Likewise, it will be studied how that miRNA signature is normalized once a substantial loss of weight is produced by the patients involved in the studied. In parallel, a comparison of the miRNA expression profiles secreted in the endometrial fluid in smoker women vs nonsmoker women will be performed. As in the previous case, it will be studied if after the exposure to these contaminant, the normalization of the miRNA expression signature occurs. Finally, an in silico analysis will be carried out in order to define the target genes and the metabolic pathways affected by the miRNAs profile secreted in both pathological conditions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The developmental origins of adult disease are now recognized to be related to intrauterine conditions during embryonic and fetal life. Pregnancy begins with embryo implantation and its impact in adult life remains unknown. It has been demonstrated that human endometrial epithelium secretes specific microRNAs (miRNAs) during the time frame when the embryo enters the uterine cavity and initiates its adhesion to the uterine wall. Maternal miRNAs are secreted to the endometrial fluid, transported through exosomes or bound to proteins and consequently uptaken by the preimplantation embryo, before implantation occurs. As a consequence they suffer transcriptomic modifications that induce profound molecular and functional changes. The data already published demonstrate a novel paradigm: the transcriptomic maternal endometrial regulation of the pre-implantation embryo in health.
Here, this novel maternal endometrium-based mechanism will be applied in order to understand and prevent the developmental origin of adult diseases induced during embryonic implantation either by metabolic disorders of future mothers who have developed obesity or by the exposure to certain contaminants such as tobacco. In this project, the expression profiles of secreted miRNAs will be identified in the endometrial fluid in obese women compared to normo-weight women. Also, it will be studied how this "obese" endometrial miRNA pattern is reversed after weight-loss. In parallel, murine models of obesity will be used to proof this concept. In addition, the expression profiles of secreted endometrial miRNAs will be identified in smokers versus future non-smokers mothers. As in the previous case, the reversion of this signature will be analysed after stopping the exposure to this contaminant.
Then, "in silico" analysis will be done to select putative genes and functional pathways targeted by the signature of secreted endometrial miRNAs in the human and murine models in both pathological conditions. The determination of the transcriptomic and/or epigenome modifications induced by "obese" or/and "smoker" endometrial miRNAs in preimplantation mouse embryos is expected. As preliminary results, to support this project our accepted model of transcriptomic maternal endometrial regulation of the pre-implantation embryo in health, and the identification of a differential pattern of secreted miRNAs in the endometrial fluid of obese women compared to normo-weight counterparts is presented. In consequence, the application of this novel endometrium-based mechanism to the understanding and prevention of the origin of adult diseases related to obesity and/or tobacco exposure is proposed.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Carlos Gomez, BSc MSc
- Phone Number: +34963905310
- Email: carlos.gomez@igenomix.es
Study Contact Backup
- Name: Diana Valbuena, MD PhD
- Phone Number: +34963905310
- Email: diana.valbuena@igenomix.es
Study Locations
-
-
-
Valencia, Spain, 46015
- Recruiting
- IVI Valencia
-
Contact:
- Carlos Simon, MD PhD
- Phone Number: +34963050900
- Email: carlos.simon@ivi.es
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Endometrial fluids from non-smoker obese and normoweight samples will be analysed in the window of implantation. In turn, endometrial fluids from normoweight smoker and non-smoker patients will be analysed in the window of implantation.
These participants will be recruited in just one centre: IVI Valencia. Their recruitment will be done through a routine consultation carried out by the research team from the centre, as well as through the revision and daily evaluation of the medical reports and subsequent contact with those patients who could accomplish with the criteria selection and desire to be involved in the study.
Description
Inclusion Criteria:
- Women with age comprised between 18 and 45 years
- Normal uterus (evaluated trough ultrasound 2D/3D and/or hysteroscopy)
- Presence of at least one ovary
- Body mass index:
- Normoweight: 18.0-24.9 kg/m2 and non smokers
- Obese ≥30.0 kg/m2 and non smokers
- Smokers: Normoweight and smoke at least 10 cigarettes per day
Exclusion Criteria:
- Overweight=25.0-29.9 kg/m2
- Patients with Intrauterine device in the last 3 months
- Patients who had had hormonal contraceptives in the 2 previous months.
- Adnexal or uterine pathologies
- Polycystic ovary
- Existence of serious or uncontrolled bacterial, fungal or viral infections that could interfere with the involvement of the patient in the study or in the evaluation of the study results.
- Any disease or medical condition that could be unstable or could endanger the security of the patient and her compliance in the study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Obese non smoker vs Normoweight non smoker
Endometrial fluid (EF) will be obtained from non-smokers normo-weight and obese patients in the receptive state.
Samples will be collected 7 days after Luteinizing Hormone (LH) peak.
They will be classified following the guidelines of the obesity classification system by the World Human Organization (WHO).
Patients will be subjected to a fitness program during a year with the aim to achieve a weight reduction to normal values (19-24.9
kg/m2).
The modifications in the miRNAs expression will be studied.
After the weight loss, new EF will be collected from these patients.
|
|
Normoweight smoker vs Normoweight non-smoker
EF will be obtained from non-smokers and smokers normo-weight in the receptive state.
Samples will be collected 7 days after Luteinizing Hormone (LH) peak.
Smokers patients will be urge to give up smoking during at least one year.
After this time, new samples will be collected to determine if the non-exposition to this contaminant could exert any effect in the miRNAs signature.
A regular control will be done in this group of patients to ensure that they have not been exposed to tobacco in 12 months.
Professional support will be given in the same centre of the study to help the patient to accomplish its objective.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Understanding of the epigenetic and transcriptomic mechanisms that regulate the FOAD
Time Frame: 40 months
|
The main objective of the present project is focused on understanding the epigenetic and transcriptomic mechanisms that regulate the fetal origin of adult diseases (FOAD) either by the presence of metabolic disorders in mothers such as obesity, or by the exposure to certain pollutants such as tobacco
|
40 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of the miRNA expression pattern in the endometrial fluid (EF) in obese patients Analysis of the miRNA expression profile in the endometrial fluid
Time Frame: 13 months
|
miRNA expression profile will be analysed in obese women , in comparison to normoweight women during the window of implantation.
In turn, the normalization of this particular transcriptomic signature will be studied after the existence of a substantial loss of weight by the patients involved in the study.
|
13 months
|
Analysis of the miRNA expression pattern in the endometrial fluid (EF) in smoker patients
Time Frame: 13 months
|
A comparison between the miRNA expression profiles in smoker women vs. non-smoker will be done in the endometrial fluid (EF) during the window of implantation.
As in the previous case, it will be studied if that particular pattern is normalized after giving up smoking.
|
13 months
|
Functional analysis
Time Frame: 13 months
|
The target genes and the metabolic routes affected by the miRNA profile secreted in both pathological conditions will be defined.
|
13 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Carlos Simón, MD PhD, Igenomix
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 1603-IGX-018-CS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fetal Origin of Adult Diseases
-
Stefania CostiArcispedale Santa Maria Nuova-IRCCSCompletedComplex Patients: Patients With High Level of Complexity Regardless of the Pathology of Origin
-
IRCCS Policlinico S. DonatoRecruitingAnomalous Aortic Origin of the Coronary Artery (AAOCA)Italy
-
National Institute of Environmental Health Sciences...Completed
-
Novartis PharmaceuticalsCompletedNeuroendocrine Tumors | Advanced NET of GI Origin | Advanced NET of Lung OriginUnited States, Colombia, Italy, Taiwan, United Kingdom, Belgium, Czechia, Germany, Japan, Saudi Arabia, Canada, Netherlands, Spain, Korea, Republic of, Lebanon, Austria, China, Greece, South Africa, Thailand, Hungary, Turkey, Poland, ... and more
-
Novartis PharmaceuticalsCompletedWell-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine CarcinomaUnited States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
-
Raydiant Oximetry, Inc.TerminatedFetal Hypoxia | Fetal Distress | Fetal Acidemia | Fetal or Neonatal Effect of Complication of LaborUnited States
-
Quinnipiac UniversitySole Supports, IncCompletedLower Extremity Pain of a Mechanical OriginUnited States
-
Reproductive Medicine Associates of New JerseyTerminated
-
Samuel Lunenfeld Research Institute, Mount Sinai...WithdrawnPsychological Sequelae of Termination of Pregnancy for Fetal AnomalyCanada
Clinical Trials on Stop smoking
-
Leiden University Medical CenterMedical Center Haaglanden; Haga Hospital; Spaarne Gasthuis; Alrijne HospitalRecruiting
-
University of California, San FranciscoCompleted
-
Center for Innovative Public Health ResearchNational Cancer Institute (NCI); The University of Texas Health Science Center... and other collaboratorsCompletedSmoking CessationUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedNicotine Dependence | Cigarette SmokingUnited States
-
Collège National des Généralistes EnseignantsAssistance Publique - Hôpitaux de Paris; Institut National de la Santé Et de... and other collaboratorsCompletedHigh Risk Hypertensive PatientsFrance
-
i4HealthCenter for Behavioral Intervention Technologies; San Francisco Health NetworkCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteUniversity of Miami; James and Esther King Biomedical Research ProgramCompletedSmoking Cessation | Tobacco DependenceUnited States
-
Peter GædeActive, not recruiting
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI); Florida Department of HealthCompleted
-
University of California, San FranciscoCompleted